Tinidazole Sodium Chloride Injection

Pharmacological action: This product has strong antibacterial effect on most anaerobic bacteria, and the antibacterial spectrum includes Bacteroides fragilis and other Bacteroides, Clostridium, Peptococcus and Peptostreptococcus, Veillonella and Sodium Adderall. A concentration of 2-4 mg/L can inhibit most anaerobic bacteria; microaerophilic bacteria and Helicobacter pylori are sensitive to it; the MIC for Trichomonas vaginalis is similar to that of metronidazole, and its metabolites have enhanced activity against Sodium Adderall than metronidazole. The bactericidal mechanism of this product has not been fully elucidated. The nitroreductase of anaerobic bacteria plays an important role in the energy metabolism of sensitive strains. The nitro group of this product is reduced to a cytotoxin, which acts on the DNA metabolism process of bacteria and promotes bacterial death. Drug-resistant bacteria often lack nitroreductase and are resistant to this product. The mechanism of this product against amoeba is to inhibit its redox reaction, break the nitrogen chain of the protozoa, and thus kill the protozoa. Toxicological studies have found that this product has carcinogenic and mutagenic effects in animal experiments or in vitro assays, but this has not been confirmed in humans.

Tinidazole. Chemical name: 2-methyl-1-[2-(ethylsulfonyl)ethyl]-5-nitro-1H-imidazole.

This product is a colorless or almost colorless clear liquid.

Used for various anaerobic infections, such as sepsis, osteomyelitis, abdominal infection, pelvic infection, and lung and bronchial infection.

Intravenous drip. 1. Anaerobic infection: 0.8g once, once a day, intravenous drip slowly, generally 5 to 6 days, or according to the condition. 2. Prevention of postoperative anaerobic infection: total amount 1.6g, drip once or twice, the first time 2 to 4 hours before surgery, the second time during surgery or within 12 to 24 hours after surgery.

Adverse reactions are rare and mild, mainly nausea, vomiting, loss of appetite and bad breath, dizziness, headache, vertigo, itchy skin, rash, constipation and general discomfort. Angioedema, neutropenia, disulfiram-like reaction and dark urine may also occur, and mild phlebitis at the infusion site may occasionally occur. High doses may also cause epileptic seizures and peripheral neuropathy.

1. Patients who are allergic to tinidazole and nitroso-imidazol derivatives are prohibited from using this product. 2. Patients with blood diseases or a history of blood diseases and patients with active central nervous system diseases are prohibited from using this product. 3. Women who are within three months of pregnancy and breastfeeding women are prohibited from using this product. 4. Patients under 12 years old are prohibited from using this product.

Precautions for children: Patients under 12 years old are prohibited from using this product. Precautions for pregnancy and lactation: This product can pass through the placenta and quickly enter the fetal circulation. Animal experiments have found that intraperitoneal administration is toxic to the fetus, while oral administration is non-toxic. There is no sufficient and strict control observation on the effect of this product on the fetus, so pregnant women should only use this product when there is a clear indication, but it should be prohibited within 3 months of pregnancy. Patients who are more than 3 months pregnant should use it with caution or follow the doctor's advice after fully weighing the pros and cons. The concentration of this product in breast milk is similar to that in blood. Animal experiments have shown that this product has a carcinogenic effect on young mice, so it is not recommended for use in lactating women. If the drug must be used, breastfeeding should be suspended, and breastfeeding can only be resumed 3 days after the end of the treatment course. Precautions for the elderly: Due to decreased liver function in the elderly, the pharmacokinetics of this product are changed when it is used, and the blood drug concentration needs to be monitored.

1. This product can inhibit the metabolism of warfarin and other oral anticoagulants, enhance their effects, and cause the prothrombin time to be prolonged. 2. The simultaneous use of drugs that induce liver microsomal enzymes, such as phenytoin sodium and phenobarbital, can enhance the metabolism of this product, reduce blood drug concentration, and slow down the excretion of phenytoin sodium. 3. The simultaneous use of drugs that inhibit the activity of liver microsomal enzymes, such as cimetidine, can slow down the metabolism and excretion of this product in the liver, and prolong the serum half-life of this product. The dosage should be adjusted according to the results of blood drug concentration determination. 4. This product interferes with the metabolism of disulfiram. Patients who use the two together may experience mental symptoms after drinking. Therefore, patients who have used disulfiram within 2 weeks should not use this product again. 5. This product can interfere with the results of aminotransferase and LDH determinations, and can reduce cholesterol and triglyceride levels.

Keep away from light, tightly closed, in a cool place.

100ml: 0.4g of tinidazole and 0.9g of sodium chloride

24 months

Henan Shuanghe Huali Pharmaceutical Co., Ltd.

• Founded in:

  2011-09-30

• Address:

  No. 369 Qinggong Road, Pingdingshan City

• Tax NO.:

  91410400582895296J

• Registered Funds:

  118 million yuan

• Website:

  Log in to view

• Email:

  Log in to view